Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Unmet needs in CML: life-threatening toxicities, QoL & dealing with intolerance and resistance

Valentin Garcia Gutiérrez • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, highlights the importance of developing novel treatment strategies for patients with chronic myeloid leukemia (CML) who experience life-threatening toxicities associated with the use of tyrosine kinase inhibitors (TKIs), as well as for patients who become resistant to TKIs, and to improve the quality of life (QoL) of patients who receive lifelong TKI therapy. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer

More from Valentin Garcia Gutiérrez

1:10
The importance of understanding TKI-specific side effects to select the best option for each patient
Valentin Garcia Gutiérrez • 21 Oct 2022
2:00
Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs
Valentin Garcia Gutiérrez • 21 Oct 2022

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals